Navigation Links
OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
Date:3/14/2011

HONG KONG, March 14, 2011 /PRNewswire/ -- OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent.  The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

Azule features OrbusNeich's unique Dual Helix stent design, offering conformability and radial strength on thin, flexible and low-profile cobalt chromium stent struts.  The stent's tip length has been reduced from 5 mm to 4.25 mm, improving deliverability and crossability.  The precise laser forming of the tip results in a lower lesion entry profile, and the controlled laser welding of the balloon to the catheter improves the stent's trackability and flexibility.

"Continuous technology advancement is mandated by our customers and the very nature of interventional cardiology," said Al Novak, OrbusNeich's Chairman and CEO.  "We believe the underlying deliverability of a stent is, and will continue to be, a critically important factor that we strive to improve."

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.  Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Recently Zymo Research announced an exclusive license ... Horvath,s Clock. Based on this technology, Zymo Research ... academic and biopharma scientific researchers to determine the ... sperm. The service quantifies changes in ... chronological age following drug treatments and identifies disease ...
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson and ... medical technology company, will demonstrate an enhanced technology platform ... technologies, including the company,s leading Pyxis™ and Alaris™ systems, ... (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent ...
(Date:12/5/2016)... 5, 2016 Research and Markets has announced ... Test Market Size, Share, Development, Growth and Demand Forecast to 2022" ... ... female fertility and pregnancy rapid test market is expected to grow ... and pregnancy rapid test market is witnessing high growth, due to ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... 2016 , ... For many years, Andrew G. Zubinas has accumulated ... beauty of the Lithuanian language and its poetry inspired him in writing ... lyrically explores all aspects of a living, breathing forest where nothing ever stays the ...
(Date:12/5/2016)... ... December 05, 2016 , ... T.E.N., ... that nominations will be accepted from December 5, 2016 through March 3, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a ... design firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, ... exclusive licensing agreement three years ago to design and develop the kathy ireland® ...
(Date:12/5/2016)... York, NY (PRWEB) , ... December 05, 2016 ... ... companies to use a patent-pending blend of L-Citrulline and glutathione to enhance production ... Blend, a combination that studies have shown to produce NO twice as effectively ...
(Date:12/5/2016)... Nashville, Tennessee (PRWEB) , ... ... ... leader in strategic interoperability, today announced that the company will provide alerting ... platform. CIHIE has been recently awarded $1.7 million in federal funds as ...
Breaking Medicine News(10 mins):